6 Best Peptides for Mast Cell Activation Syndrome (MCAS)
Six peptides show up consistently in MCAS research and community discussions as adjunctive tools alongside standard antihistamine and mast cell stabilizer protocols: GLP-1 receptor agonists (tirzepatide and semaglutide), KPV, BPC-157, VIP, Thymosin Alpha-1, and MOTS-c. They are ordered here by how prominently each appears in the research and in real-world use, not ranked as recommendations of one over another. The honest overall picture is that formal human trial data is thin to nonexistent for most of them, with GLP-1 receptor agonists standing apart as the only compounds with published human evidence specifically for MCAS. Understanding where each one stands before talking to a clinician is exactly what this guide is built to help with.
